Access our full library of guidance, white papers, and other resources developed by and for the medical technology industry.
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to…
AdvaMed® periodically compiles benchmarking data on Member companies’ policies regarding the provision of meals and refreshments to U.S. Health Care Professionals to assist companies in understanding industry trends and practices…
Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy
AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to…
Achieve the highest levels of compliance with principles on consulting arrangements, training, education and other forms of communications.
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
AdvaMed® periodically compiles benchmarking data on Member companies’ compliance policies regarding travel and lodging for U.S. Health Care Professionals to assist companies in understanding industry trends and practices when the…
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.
Member-only overview of IEEPA reciprocal & “fentanyl” tariffs under EO 14257, summarizing key federal court challenges and rulings through August 15, 2025.